These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 7825689)

  • 1. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
    Thompson JT; Glaser BM; Sjaarda RN; Murphy RP
    Am J Ophthalmol; 1995 Jan; 119(1):48-54. PubMed ID: 7825689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes.
    West S
    Am J Ophthalmol; 1995 Jun; 119(6):819. PubMed ID: 7785710
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of patient age and intraocular gas use in cataract progression after vitrectomy for macular holes and epiretinal membranes.
    Thompson JT
    Am J Ophthalmol; 2004 Feb; 137(2):250-7. PubMed ID: 14962413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reoperation after failed macular hole surgery.
    Smiddy WE; Sjaarda RN; Glaser BM; Flynn HW; Thompson JT; Hanham A; Murphy RP
    Retina; 1996; 16(1):13-8. PubMed ID: 8927804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of vitreous surgery for chronic macular holes.
    Thompson JT; Sjaarda RN; Lansing MB
    Retina; 1997; 17(6):493-501. PubMed ID: 9428011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retreatment of full-thickness macular holes persisting after prior vitrectomy. A pilot study.
    Ie D; Glaser BM; Thompson JT; Sjaarda RN; Gordon LW
    Ophthalmology; 1993 Dec; 100(12):1787-93. PubMed ID: 8259275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes.
    Lansing MB; Glaser BM; Liss H; Hanham A; Thompson JT; Sjaarda RN; Gordon AJ
    Ophthalmology; 1993 Jun; 100(6):868-71; discussion 871-2. PubMed ID: 8510899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
    Blumenkranz MS; Ohana E; Shaikh S; Chang S; Coll G; Morse LS; De Bustros S
    Ophthalmic Surg Lasers; 2001; 32(3):198-207. PubMed ID: 11371086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular hole surgery without face-down positioning. A pilot study.
    Tornambe PE; Poliner LS; Grote K
    Retina; 1997; 17(3):179-85. PubMed ID: 9196926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cataract extraction after diabetic vitrectomy.
    Smiddy WE; Feuer W
    Retina; 2004 Aug; 24(4):574-81. PubMed ID: 15300079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term anatomic and visual acuity outcomes after initial anatomic success with macular hole surgery.
    Scott IU; Moraczewski AL; Smiddy WE; Flynn HW; Feuer WJ
    Am J Ophthalmol; 2003 May; 135(5):633-40. PubMed ID: 12719070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitrectomy, fluid-gas exchange and transforming growth factor--beta-2 for the treatment of traumatic macular holes.
    Rubin JS; Glaser BM; Thompson JT; Sjaarda RN; Pappas SS; Murphy RP
    Ophthalmology; 1995 Dec; 102(12):1840-5. PubMed ID: 9098285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical treatment of macular holes with multiple recurrences.
    Thompson JT; Sjaarda RN
    Ophthalmology; 2000 Jun; 107(6):1073-7. PubMed ID: 10857825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phacovitrectomy with internal limiting membrane peeling for idiopathic macular hole.
    Gottlieb CC; Martin JA
    Can J Ophthalmol; 2002 Aug; 37(5):277-82; discussion 282. PubMed ID: 12322859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.
    Minihan M; Goggin M; Cleary PE
    Br J Ophthalmol; 1997 Dec; 81(12):1073-9. PubMed ID: 9497468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2.
    Thompson JT; Glaser BM; Sjaarda RN; Murphy RP; Hanham A
    Ophthalmology; 1994 Jul; 101(7):1195-200. PubMed ID: 8035983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study.
    Glaser BM; Michels RG; Kuppermann BD; Sjaarda RN; Pena RA
    Ophthalmology; 1992 Jul; 99(7):1162-72; discussion 1173. PubMed ID: 1495798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.
    Thompson JT; Smiddy WE; Williams GA; Sjaarda RN; Flynn HW; Margherio RR; Abrams GW
    Ophthalmology; 1998 Apr; 105(4):700-6. PubMed ID: 9544645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rate of reopening of macular holes following cataract operation].
    Hager A; Ehrich S; Wiegand W
    Ophthalmologe; 2007 May; 104(5):388-92. PubMed ID: 17406812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of vitreoretinal surgery in the treatment of posttraumatic macular hole.
    García-Arumí J; Corcostegui B; Cavero L; Sararols L
    Retina; 1997; 17(5):372-7. PubMed ID: 9355183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.